Q4 2022 Results
Company overview
Innovation: Pipeline overview
Cardiovascular
Ophthalmology
Financial review
Immunology
aflibercept - VEGF inhibitor
NCT04864834 Mylight (CSOK583A12301)
Ophthalmology indication (as originator)
Phase 3
Indication
Phase
Patients
460
2023 priorities
Innovation: Clinical trials
Neuroscience
Global Health
Primary
Outcome
Measures
Arms
Intervention
Best-corrected visual acuity (BCVA) will be assessed using the ETDRS testing
charts at an initial distance of 4 meters. The change from baseline in BCVA in
letters is defined as difference between BCVA score between week 8 and
baseline
Arm 1 Biological: SOK583A1 (40 mg/mL)
Arm 2 Biological: Eylea EU (40 mg/mL)
Patients with neovascular age-related macular degeneration
Target
Patients
Readout
2023
Milestone(s)
Publication
tbd
Appendix
Abbreviations
Oncology
Other
Biosimilars
105 Investor Relations | Q4 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation